Gufic BioSciences Ltd (GUFICBIO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 338998,
    "name": "Gufic BioScience",
    "stock_name": "Gufic BioScience",
    "full_name": "Gufic BioSciences Ltd",
    "name_url": "stocks-analysis/gufic-bioscience",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "303.20",
    "chg": 7.3,
    "chgp": "2.47%",
    "dir": 1,
    "prev_price": "295.90",
    "mcapval": "3,040.57 Cr",
    "mcap": "Small Cap",
    "scripcode": 509079,
    "symbol": "GUFICBIO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE742B01025",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "43.48 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/gufic-bioscience-338998-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Gufic BioScience overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-gufic-bioscience-overvalued-or-undervalued-3745251",
        "imagepath": "",
        "date": "2025-12-04 08:18:22",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Valuation Metrics Indicate Elevated Pricing</strong></p>\n<p>At a price-to-earnings (PE) ratio of 61.6, Gufic BioScience trades at a significant premium compared to many of its pharmaceutical peers. This elevated PE suggests that investors are pricing in strong future growth, but it also implies a higher risk if growth expectations are not met. The price-to-book (P/B) ratio of 5.56 further underscores the premium valuation, indicating that the market values the company at over five times its net asset value.</p>\n<p>Enterprise value (EV) multiples also reflect this expensive stance. The EV to EBIT ratio stands at 36.6, and EV to EBITDA at 28.8, both considerably higher than industry averages. These multiples suggest that the market expects robust earnings before interest and taxes, as well as ..."
      },
      {
        "title": "Gufic BioScience Sees Revision in Market Evaluation Amidst Challenging Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gufic-bioscience-downgraded-to-strong-sell-amid-weak-financials-and-valuation-concerns-3735096",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GuficBioScience_mojoScore_3735096.png",
        "date": "2025-11-28 10:05:47",
        "description": "Gufic BioScience, a small-cap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a period marked by subdued profitability and valuation concerns, impacting investor sentiment and stock performance."
      },
      {
        "title": "Why is Gufic BioScience falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-gufic-bioscience-fallingrising-3726570",
        "imagepath": "",
        "date": "2025-11-25 00:25:15",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>On 24 November, Gufic BioSciences closed at ₹354.65, up by ₹1.45 or 0.41%. This uptick is part of a broader short-term rally, with the stock gaining 12.66% over the past week, significantly outperforming the Sensex, which was nearly flat with a marginal decline of 0.06% during the same period. Over the last month, the stock also outpaced the benchmark, delivering a 3.93% return compared to the Sensex’s 0.82% rise.</p>\n<p>Notably, the stock has been on a consecutive five-day gain streak, touching an intraday high of ₹374.20 on the day, marking a 5.95% increase from recent lows. This positive price action has been supported by rising investor participation, with delivery volumes on 21 November increasing by 36.51% compared to the fiv..."
      },
      {
        "title": "Gufic BioSciences Sees Shift in Technical Momentum Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gufic-biosciences-sees-technical-momentum-shift-amid-mixed-market-signals-3723648",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GuficBioScience_technicaldot_3723648.png",
        "date": "2025-11-24 08:01:29",
        "description": "Gufic BioSciences, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a nuanced market assessment. Recent price movements and technical indicators suggest a transition from a predominantly bearish stance to a more mildly bearish outlook, underscoring evolving investor sentiment and market dynamics."
      },
      {
        "title": "Why is Gufic BioScience falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-gufic-bioscience-fallingrising-3715983",
        "imagepath": "",
        "date": "2025-11-19 21:49:16",
        "description": "As of 19-Nov, Gufic BioSciences Ltd is experiencing a price increase, currently at 335.05, reflecting a rise of 5.35 (1.62%). The stock has shown a positive performance today, outperforming its sector by 1.55% and achieving a consecutive gain over the last two days with a total return of 6.43%. Additionally, the stock reached an intraday high of Rs 348, indicating strong intraday trading activity. The delivery volume has significantly increased, rising by 335.29% against the 5-day average, suggesting heightened investor interest. However, the stock's performance over the past month shows a decline of 4.72%, and it has a year-to-date drop of 26.05%, indicating some underlying challenges despite the recent gains.\n\nIn the broader market context, Gufic BioSciences' short-term return of +1.36% over the past week outperformed the Sensex, which increased by 0.85%. This indicates that while the stock has faced long..."
      },
      {
        "title": "Are Gufic BioScience latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-gufic-bioscience-latest-results-good-or-bad-3712656",
        "imagepath": "",
        "date": "2025-11-18 19:29:07",
        "description": "Gufic BioSciences recently reported its financial results for Q2 FY26, revealing a complex picture of performance. The company achieved record net sales of ₹237.05 crores, reflecting a year-on-year growth of 16.10% and a sequential increase of 5.96%. However, this top-line growth was overshadowed by significant challenges on the profitability front. \n\nNet profit for the quarter stood at ₹16.82 crores, which represents a year-on-year decline of 22.74%. The profit after tax (PAT) margin also contracted to 7.10%, down from 10.66% in the same quarter last year. This decline in profitability can be attributed to a sharp rise in interest costs, which surged by 84.94% year-on-year to ₹9.58 crores, consuming a substantial portion of operating profits. Additionally, the operating margin decreased to 15.96%, a contraction of 295 basis points compared to the previous year, indicating deteriorating operational efficien..."
      },
      {
        "title": "Gufic BioSciences Q2 FY26: Margin Pressures Cloud Revenue Growth Amid Rising Interest Burden",
        "link": "https://www.marketsmojo.com/news/result-analysis/gufic-biosciences-q2-fy26-margin-pressures-cloud-revenue-growth-amid-rising-interest-burden-3711330",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GuficBioScience_quaterlyResult_3711330.png",
        "date": "2025-11-17 23:09:10",
        "description": "Gufic BioSciences Ltd., a Mumbai-based pharmaceutical manufacturer with a market capitalisation of ₹3,199 crores, reported a challenging quarter ended September 2025, with net profit declining 22.74% year-on-year to ₹16.82 crores despite posting its highest-ever quarterly revenue. The stock has tumbled 29.82% over the past year, significantly underperforming both the Sensex and the broader pharmaceuticals sector, reflecting investor concerns over deteriorating profitability metrics and mounting interest costs."
      },
      {
        "title": "How has been the historical performance of Gufic BioScience?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-gufic-bioscience-3708534",
        "imagepath": "",
        "date": "2025-11-17 22:54:08",
        "description": "Answer:\nThe historical performance of Gufic BioScience shows a mixed trend in its financial metrics for the fiscal year ending March 2025 compared to March 2024.\n\nBreakdown:\nGufic BioScience reported net sales of 819.81 Cr in March 2025, a slight increase from 806.67 Cr in March 2024. Total operating income also rose to 819.81 Cr from 806.67 Cr. However, total expenditure increased to 685.12 Cr from 660.79 Cr, leading to a decrease in operating profit (PBDIT) from 148.06 Cr to 138.32 Cr. Profit before tax fell to 94.14 Cr from 115.67 Cr, and profit after tax decreased to 69.65 Cr from 86.14 Cr, reflecting a decline in profitability. The earnings per share (EPS) also dropped from 8.59 to 6.94. On the balance sheet, total assets increased to 1,169.36 Cr from 1,092.54 Cr, while total liabilities rose to 1,169.36 Cr from 1,092.54 Cr, indicating a stable financial position. Cash flow from operating activities im..."
      },
      {
        "title": "How has been the historical performance of Gufic BioScience?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-gufic-bioscience-3702886",
        "imagepath": "",
        "date": "2025-11-14 23:37:02",
        "description": "Answer:\nThe historical performance of Gufic BioScience shows a mixed trend in its financial metrics from March 2024 to March 2025.\n\nBreakdown:\nGufic BioScience reported net sales of 819.81 Cr in March 2025, a slight increase from 806.67 Cr in March 2024. Total operating income also rose to 819.81 Cr from 806.67 Cr, while total expenditure increased to 685.12 Cr from 660.79 Cr. The operating profit (PBDIT) decreased to 138.32 Cr from 148.06 Cr, reflecting a decline in the operating profit margin from 18.08% to 16.43%. Profit before tax fell to 94.14 Cr from 115.67 Cr, leading to a profit after tax of 69.65 Cr, down from 86.14 Cr, resulting in a PAT margin decrease from 10.68% to 8.5%. On the balance sheet, total liabilities rose to 1,169.36 Cr from 1,092.54 Cr, while total assets also increased to 1,169.36 Cr from 1,092.54 Cr. Cash flow from operating activities improved significantly to 122.00 Cr from -7.00..."
      }
    ],
    "total": 510,
    "sid": "338998",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/gufic-biosciences-338998"
  },
  "announcements": [
    {
      "caption": "Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "20-Jan-2026",
      "details": "Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 is attached herewith",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "06-Jan-2026",
      "details": "Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended December 31 2025 is attached herewith",
      "source": "BSE"
    },
    {
      "caption": "Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "27-Dec-2025",
      "details": "Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 is attached herewith.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Gufic BioSciences Ltd has declared <strong>10%</strong> dividend, ex-date: 22 Sep 25",
          "dt": "2025-09-22",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Gufic BioScience overvalued or undervalued?

2025-12-04 08:18:22

Valuation Metrics Indicate Elevated Pricing At a price-to-earnings (PE) ratio of 61.6, Gufic BioScience trades at a significant premium compared to many of its pharmaceutical peers. This elevated PE suggests that investors are pricing in strong future growth, but it also implies a higher risk if growth expectations are not met. The price-to-book (P/B) ratio of 5.56 further underscores the premium valuation, indicating that the market values the company at over five times its net asset value. Enterprise value (EV) multiples also reflect this expensive stance. The EV to EBIT ratio stands at 36.6, and EV to EBITDA at 28.8, both considerably higher than industry averages. These multiples suggest that the market expects robust earnings before interest and taxes, as well as ...

Gufic BioScience Sees Revision in Market Evaluation Amidst Challenging Financial Trends

2025-11-28 10:05:47

Gufic BioScience, a small-cap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a period marked by subdued profitability and valuation concerns, impacting investor sentiment and stock performance.

Why is Gufic BioScience falling/rising?

2025-11-25 00:25:15

Recent Price Movement and Market Performance On 24 November, Gufic BioSciences closed at ₹354.65, up by ₹1.45 or 0.41%. This uptick is part of a broader short-term rally, with the stock gaining 12.66% over the past week, significantly outperforming the Sensex, which was nearly flat with a marginal decline of 0.06% during the same period. Over the last month, the stock also outpaced the benchmark, delivering a 3.93% return compared to the Sensex’s 0.82% rise. Notably, the stock has been on a consecutive five-day gain streak, touching an intraday high of ₹374.20 on the day, marking a 5.95% increase from recent lows. This positive price action has been supported by rising investor participation, with delivery volumes on 21 November increasing by 36.51% compared to the fiv...

Gufic BioSciences Sees Shift in Technical Momentum Amid Mixed Market Signals

2025-11-24 08:01:29

Gufic BioSciences, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a nuanced market assessment. Recent price movements and technical indicators suggest a transition from a predominantly bearish stance to a more mildly bearish outlook, underscoring evolving investor sentiment and market dynamics.

Why is Gufic BioScience falling/rising?

2025-11-19 21:49:16

As of 19-Nov, Gufic BioSciences Ltd is experiencing a price increase, currently at 335.05, reflecting a rise of 5.35 (1.62%). The stock has shown a positive performance today, outperforming its sector by 1.55% and achieving a consecutive gain over the last two days with a total return of 6.43%. Additionally, the stock reached an intraday high of Rs 348, indicating strong intraday trading activity. The delivery volume has significantly increased, rising by 335.29% against the 5-day average, suggesting heightened investor interest. However, the stock's performance over the past month shows a decline of 4.72%, and it has a year-to-date drop of 26.05%, indicating some underlying challenges despite the recent gains. In the broader market context, Gufic BioSciences' short-term return of +1.36% over the past week outperformed the Sensex, which increased by 0.85%. This indicates that while the stock has faced long...

Are Gufic BioScience latest results good or bad?

2025-11-18 19:29:07

Gufic BioSciences recently reported its financial results for Q2 FY26, revealing a complex picture of performance. The company achieved record net sales of ₹237.05 crores, reflecting a year-on-year growth of 16.10% and a sequential increase of 5.96%. However, this top-line growth was overshadowed by significant challenges on the profitability front. Net profit for the quarter stood at ₹16.82 crores, which represents a year-on-year decline of 22.74%. The profit after tax (PAT) margin also contracted to 7.10%, down from 10.66% in the same quarter last year. This decline in profitability can be attributed to a sharp rise in interest costs, which surged by 84.94% year-on-year to ₹9.58 crores, consuming a substantial portion of operating profits. Additionally, the operating margin decreased to 15.96%, a contraction of 295 basis points compared to the previous year, indicating deteriorating operational efficien...

Gufic BioSciences Q2 FY26: Margin Pressures Cloud Revenue Growth Amid Rising Interest Burden

2025-11-17 23:09:10

Gufic BioSciences Ltd., a Mumbai-based pharmaceutical manufacturer with a market capitalisation of ₹3,199 crores, reported a challenging quarter ended September 2025, with net profit declining 22.74% year-on-year to ₹16.82 crores despite posting its highest-ever quarterly revenue. The stock has tumbled 29.82% over the past year, significantly underperforming both the Sensex and the broader pharmaceuticals sector, reflecting investor concerns over deteriorating profitability metrics and mounting interest costs.

How has been the historical performance of Gufic BioScience?

2025-11-17 22:54:08

Answer: The historical performance of Gufic BioScience shows a mixed trend in its financial metrics for the fiscal year ending March 2025 compared to March 2024. Breakdown: Gufic BioScience reported net sales of 819.81 Cr in March 2025, a slight increase from 806.67 Cr in March 2024. Total operating income also rose to 819.81 Cr from 806.67 Cr. However, total expenditure increased to 685.12 Cr from 660.79 Cr, leading to a decrease in operating profit (PBDIT) from 148.06 Cr to 138.32 Cr. Profit before tax fell to 94.14 Cr from 115.67 Cr, and profit after tax decreased to 69.65 Cr from 86.14 Cr, reflecting a decline in profitability. The earnings per share (EPS) also dropped from 8.59 to 6.94. On the balance sheet, total assets increased to 1,169.36 Cr from 1,092.54 Cr, while total liabilities rose to 1,169.36 Cr from 1,092.54 Cr, indicating a stable financial position. Cash flow from operating activities im...

How has been the historical performance of Gufic BioScience?

2025-11-14 23:37:02

Answer: The historical performance of Gufic BioScience shows a mixed trend in its financial metrics from March 2024 to March 2025. Breakdown: Gufic BioScience reported net sales of 819.81 Cr in March 2025, a slight increase from 806.67 Cr in March 2024. Total operating income also rose to 819.81 Cr from 806.67 Cr, while total expenditure increased to 685.12 Cr from 660.79 Cr. The operating profit (PBDIT) decreased to 138.32 Cr from 148.06 Cr, reflecting a decline in the operating profit margin from 18.08% to 16.43%. Profit before tax fell to 94.14 Cr from 115.67 Cr, leading to a profit after tax of 69.65 Cr, down from 86.14 Cr, resulting in a PAT margin decrease from 10.68% to 8.5%. On the balance sheet, total liabilities rose to 1,169.36 Cr from 1,092.54 Cr, while total assets also increased to 1,169.36 Cr from 1,092.54 Cr. Cash flow from operating activities improved significantly to 122.00 Cr from -7.00...

View All News